Car-t cell therapy for generalized myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have antibodies against AChR or MuSK proteins
- Your MG is class II to IV
- Your MG-ADL score is at least 6 and QMG score at least 11
- You have tried 2 or more immune-suppressing treatments or need regular IVIG/plasmapheresis
- You are on stable doses of your current MG medicines for at least 1 month (or 2 months for azathioprine)
- You have not used rituximab or similar drugs in the past 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis (gMG) that is not well controlled with current treatments. The goal is to see if it can reduce symptoms and improve quality of life.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This trial tests a new type of cell therapy called STAR-T cells for adults with generalized myasthenia gravis whose symptoms are not well controlled with current treatments. The goal is to stop the immune system from attacking the body's own tissues, which might reduce muscle weakness.
This trial tests an experimental therapy using special immune cells (UCAR T-cells) to target and destroy certain B cells that produce the antibodies causing myasthenia gravis. It's for people whose symptoms are not well controlled by standard treatments and may offer a new option.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.